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Abstract
MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression with impor-
tant roles in cancer, cardiovascular and neurological disorders. Present in the brain, they 
play numerous regulatory roles shaping the proteome in an orchestrated manner with 
other non-coding RNAs. An independent brain-specific renin-angiotensin system (RAS) 
exists that is subject to miRNA remodelling. The brain RAS regulates cerebral blood flow 
and electrolytic balance and is involved in neurotransmitter signalling and cognitive pro-
cesses. Circulating microRNAs allow interaction between systemic and local RAS in the 
heart and the brain. Their screening and manipulation may be valuable towards under-
standing pathophysiology and development of treatments for various systemic and cen-
tral nervous system diseases.
Keywords: non-coding RNAs, microRNAs, brain renin-angiotensin system, 
cerebrovascular disease, circulating microRNAs, biomarkers
1. Introduction
High blood pressure, leading to cardiovascular and cerebrovascular disorders, is the princi-
pal cause of morbidity and mortality worldwide [1–3]. The renin-angiotensin system (RAS) 
is a major regulator of cardiovascular function and pharmaceutical compounds targeting the 
RAS are frontline treatments to control high blood pressure [4, 5]. In addition, lifestyle risk 
factors such as obesity, insulin resistance, high alcohol and salt intake and ageing promote 
the development of hypertension through epigenetic mechanisms [6–9]. These mechanisms 
have attracted attention because of their reversibility by environmental and lifestyle modi-
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fications, making them important in the detection and treatment of multifactorial diseases 
such as hypertension [7, 10].
Some of those epigenetic modifications are mediated by miRNAs, defined as single-stranded, 
non-coding RNA sequences approximately 21–23 nucleotides in length, expressed under 
physiological and pathological conditions [11, 12]. Deletion of complexes involved in miRNA 
biogenesis resulted in deleterious and non-viable phenotypes, highlighting their necessary 
involvement in the cellular development and differentiation [13, 14]. To date, 28,645 miRNAs 
have been reported in miRbase, a widely used resource for miRNA cataloging and nomen-
clature [15]. As epigenetic regulators of gene expression, functions of miRNAs include RNA 
degradation, inhibition of protein expression, regulation of methylation and histone modifi-
cation on DNA [12, 14, 16]. miRNAs perform these functions by complementary base pairing 
Figure 1. The renin-angiotensin system (RAS) and its components. This schematic depicts angiotensin ligands, receptors 
and the main enzymes involved; other peptidases and cathepsins also participate although to a lesser extent. All of the 
components of the RAS are present in the brain. RAS has two main axes: the pressor axis (tending towards an increase 
in blood pressure) comprising Ang II, ACE and AT1Rs and the counter-regulatory axis comprising Ang(1–7), ACE2 and 
MasR. Angiotensinogen is a substrate for renin to produce angiotensin I (Ang I), which is the inactive precursor of all 
angiotensin peptides. Conversion of Ang I to its most active ligand in the pressor axis, angiotensin II (Ang II), results 
from ACE-mediated hydrolysis [22]. Ang II is then sequentially converted to angiotensin III (Ang III) and angiotensin 
IV (Ang IV) by aminopeptidase A (APA) and aminopeptidase N (APN) respectively, which can be further cleaved by 
carboxypeptidase P (CP) and prolyl oligopeptidase (PO) to form angiotensin 3–7 (Ang3–7). Alternatively, Ang II can 
be converted, via the counter-regulatory axis to angiotensin 1–7 (Ang1–7) by carboxypeptidase P (CP) or ACE2, while 
both angiotensin A and Ang1–7 can be converted to alamandine by an ACE-mediated decarboxylation reaction [22–27]. 
Notably, angiotensin ligands acting on AT4R (also called insulin-regulated aminopeptidase (IRAP)) can have agonist or 
antagonist effects depending on whether or not they bind in the IRAP peptidase domain.
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to the target mRNAs through a seed-pairing region of 6–8 nucleotides at the 5′ end of the 
miRNA. They also interact with other non-coding RNAs and mediate proteome remodelling. 
Non-coding RNAs represent 98% of the genome, comprising transfer and ribosomal RNA, 
small nuclear (snRNA) and nucleolar RNA (snoRNA), small interference RNA (siRNA), Piwi-
interacting RNA (piRNA) and long non-coding RNAs (lncRNA) [14, 17, 18].
Dysregulation of miRNAs is associated with cancer, cardiovascular and neurodegenerative 
disorders. The RAS, with important signalling roles in numerous organs and regulatory path-
ways and being subject to miRNA-mediated remodelling, is a potential factor in many dis-
orders. Thus, the presence of miRNAs that have the capacity to shift the balance between 
prominent and deleterious functions of the RAS to beneficial roles is interesting, particularly 
new advances in methods that allow the detection of circulating miRNAs. Exosomes and 
their role in cellular transport provide a source for miRNA profiling and the presence of miR-
NAs in the peripheral circulation suggests that they work in an autocrine, paracrine and also 
endocrine manner, allowing widespread distribution of miRNAs through the entire body. 
Therefore, screening of miRNA in biological fluids like a serum and cerebrospinal fluid is 
relevant for an understanding of normal function as well as pathophysiology with a view to 
potential novel treatments for the disease.
The discovery of local independent but interacting RAS systems, including the brain, which 
also interacts with systemic RAS [3], has helped to change the original view that the RAS was 
solely an endocrine system important in regulating blood pressure, electrolytic homeostasis, 
vascular injury and repair [19]. The brain RAS discussed here (Figure 1) is multifunctional 
including regulation of cerebral blood flow, electrolyte balance, neurotransmitters, learning 
and memory, many of which may be associated with certain neurological disorders [20, 21].
2. Biogenesis and function of miRNAs
Canonical miRNA biogenesis starts with transcription of the primary miRNA sequence by 
RNA polymerase II and III [14]. Approximately half (52%) of human miRNAs are located in 
intergenic regions, 40% in intronic and 8% in exonic [28]. Intergenic miRNAs are indepen-
dently expressed through promoter elements; yet related miRNAs that often have overlapping 
targets can be located on different chromosomes and expressed under different conditions. 
Intronic and exonic miRNAs that are clustered within 50 kilobases from each other show 
similar expression, while those spaced further apart tend not to [29]. However, there are some 
exceptions. Some miRNAs separated by more than 50 kilobases retain high correlation, likely 
as a result of co-expression [30]. The differential localization and expression of miRNAs sug-
gest an evolutionary response to environmental insults and specific cell responses, a theory 
supported by observed higher numbers of miRNAs expressed in organisms of higher com-
plexity [31–33]. 
Figure 2A–F summarizes the process of miRNA biogenesis. Primary miRNAs are cleaved in 
the nucleus by a nuclear microprocessor complex comprised of the RNase III endoribonu-
clease DROSHA and its double-stranded RNA-binding protein DGCR8—DiGeorge Critical 
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Region 8, Figure 2A [34]. This cleavage by DROSHA/DGCR8 produces a 60 nucleotide stem-
loop structure with a 3′ overhang, the pre-miRNA [11, 34, 35]. The primary miRNA can also 
be further subjected to RNA editing by ADARs (adenosine deaminases acting on RNA) that 
modify adenosine to inosine producing miRNA isoforms called isomiRs [36].
Exportin 5 allows export of the pre-miRNA to the cytoplasm, Figure 2B [36], where Dicer and 
substrate stabilizing binding partners, TRBP (trans-activation response RNA-binding pro-
tein) and PACT (protein activator of RNA-activated protein kinase) facilitate conversion into 
mature miRNA, Figure 2C [12, 14]. Two strands result from the unwinding of the duplex, the 
guide (3p) and passenger (5p) strands. Most of miRNA effects are mediated by the 3′ form; the 
5′ form comprises <10% of all miRNA reads in humans [36]. The guide strand is loaded into 
the RNA-induced silencing complex (RISC) and the passenger strand is degraded by RNases, 
Figure 2D. IsomiRs can also be produced at this step by trimming and capping of the mature 
miRNA.
Figure 2. MicroRNA biogenesis and function. (A) Primary miRNAs are cleaved in the nucleus by the RNase III 
endoribonuclease DROSHA and DGCR8. (B) Once the primary miRNA is cleaved, the nuclear transport receptor 
exportin 5 binds the 3′ overhang structure of the pre-miRNA to export it to the cytoplasm. (C) The RNase III enzyme 
Dicer and TRBP and PACT target the pre-miRNA through the 3′ overhang, converting it into mature miRNA, liberating a 
duplex nucleotide structure with two nucleotides protruding at the 3′ end. (D) The guide strand is loaded into the RNA-
induced silencing complex (RISC), and the passenger strand is degraded by RNases. (E) Complementary pairing with 
the seed region to mRNAs determines target binding and guides argonaute proteins to stop translation. Accumulation 
of untranslated mRNA in the cytoplasm allows recruitment of members of the GW182 protein family. (F) Deadenylase 
complexes cause destabilization of the transcript and further degradation by RNase activity.
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Non-canonical miRNA biogenesis is independent of DROSHA/DGCR8 processing in the 
nucleus. Such biogenesis arises if an intron is spliced lacking the sequences ordinarily flank-
ing the stem region of a primary miRNA and it is of sufficient size to generate a pre-miRNA 
and it can be exported to the cytoplasm and further processed as a pre-miRNA to form a 
mirtron. Alongside mirtrons, other RNA sequences derived from transfer RNA and small 
nucleolar RNA are loaded into an RISC complex and act as miRNAs [13, 14, 29].
The RISC is a ribonucleoprotein complex that mediates mRNA degradation, destabilization 
or translational inhibition, whatever the biogenesis mechanism and comprises the miRNA 
guide strand and argonaute proteins, Figure 2E. The complementary base pairing of the 
miRNA seed region (2nd to 8th position on the 5′ end) to mRNAs determines target bind-
ing and guides argonaute proteins [28, 37, 38]. miRNA levels are dependent on argonaute 
proteins [39, 40] that are also present in the nucleus and currently, only miRNA-29b has been 
shown to translocate and localize in the nucleus [14, 39, 41]. In humans, argonaute 2 (also 
called eukaryotic translation initiation factor 2C) cleaves target mRNAs [29] but can also block 
other translation initiator factors and ribosomal subunits [42].
After pairing of the miRNA seed region, protein translation can be inhibited, Figure 2E. 
Accumulation of untranslated mRNA in the cytoplasm allows argonaute 2 to recruit members 
of the GW182 protein family, which are enriched in cytoplasmic areas called processing bodies 
(p-bodies) [42]. Here, the mRNA is destabilized by deadenylase complexes and further degraded 
by RNases [43–45]. Finally, the effect miRNAs have on protein or mRNA levels depends on the 
position where the miRNA binds and five different classes of miRNA binding have been deter-
mined [12, 46, 47]. Most miRNA effects are mediated by binding at the 3′ UTR of mRNA and 
further processing as described previously, non-canonical binding sites represent <1% [48].
3. MicroRNAs as autocrine, paracrine and endocrine molecules
miRNAs not only shape the intracellular proteome within specific cell types in response to 
microenvironment stimuli and cues, but can also mediate intercellular effects by means of 
nanotubes, exosomes and binding proteins, all mechanisms of intercellular communication 
[49]. Moreover, extracellular vesicles, including exosomes, microvesicles and apoptotic bod-
ies, also participate in paracrine and endocrine signalling, as well as an intercellular transfer of 
miRNAs [50–52]. Exosomes, in particular, which are nanovesicles derived from endosomes are 
involved in cell-to-cell communication [53], contain significant amounts of miRNAs and are 
resistant to changes in temperature, pH and the effect of RNases making them reliable sources 
for screening [51, 54, 55]. miRNAs are transported by RNA-binding proteins and are taken up 
into intraluminal vesicles during the formation of multivesicular bodies in endosomes [56]. 
Upon fusion of the endosome to the plasma membrane, the intraluminal vesicles are released 
as exosomes and due to their lipid composition and size, they can easily transfer genetic mate-
rial across lipid membranes [55, 56]. Several miRNAs are transferred in vivo and in vitro 
between fibroblasts, cardiomyocytes, human umbilical endothelial cells, mesenchymal stem 
cells, cardiac and cerebral endothelial cells [57, 58], while atheroprotective  communication has 
been found between endothelial and smooth muscle cells through miRNAs [59].
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miRNA transfer both propagates deleterious effects and helps recover cells from insults and 
prevent apoptosis. For example, miR-133 is increased in people with cardiovascular disease 
and is transferred through exosomes from multipotent mesenchymal stromal cells to astro-
cytes and neurons that promote recovery after stroke [60–63]. Furthermore, remote ischaemic 
conditioning, a technique of small cycles of ischaemia/reperfusion in distal extremities, was 
protective for cardiac and cerebrovascular effects in animal experiments and human clinical 
trials, with effects mediated by miRNAs such as miR-1 [64–69].
Exosomal circulating miRNAs have many properties that arguably make them ideal biomark-
ers, including their presence in peripheral blood, detection in many biological fluids, their 
stability in RNase-rich body fluids and their tissue-specific expression patterns. These have 
been described in cardio-cerebrovascular disorders, diabetes, dyslipidemia and neurodegen-
erative disorders [1, 70–76]. Furthermore, human exosomes can be used therapeutically as a 
gene delivery vector to provide cells with heterologous miRNAs [53].
4. Regulation of RAS by associated microRNAs
Given that there is further discussion of the biochemical functions of the RAS in other chap-
ters, the discussion henceforth will focus on some of the most important components of the 
brain RAS and the miRNAs targeting them.
Since the vital function of the brain results in high physiological demands (i.e. requiring 20% 
of total cardiac output and a 10-fold higher oxygen and energy demand than other tissues), it 
requires strict coordination between blood flow and neuronal activity, a phenomena known as 
functional hyperaemia [77]. Cerebral blood flow is regulated by vasomotor, metabolic and neu-
rogenic mechanisms, but can be modulated by vasoconstrictors such as Ang II and endothelin, 
vasodilators such as bradykinin, adenosine and other angiotensin ligands, while blood vessel 
capacity may be reduced or impeded by plaques of cholesterol, amyloid or fibrotic deposits.
Analysis by TargetScan [48], a software that predicts miRNA binding sites, suggests that 368 
different miRNA families target RAS elements, the majority of which share transcripts. Table 1 
summarizes the total number of miRNAs and unique miRNAs with respect to RAS elements, 
as they have other targets outside the RAS. Angiotensin 4 receptor (also known as AT4R or 
IRAP) has 252 miRNA families associated with it, making it the highest amongst the RAS and 
approximately fivefold and threefold as many as that for arguably its better known recep-
tors AT1R and AT2R. Notably, 88% of IRAP-associated miRNAs also regulate other RAS tran-
scripts, suggesting its susceptibility to changes elsewhere in the RAS. In particular, IRAP has 
28 miRNA families exclusively associated with it (also the most for RAS components), hinting 
at having high functional importance. Indeed, aminopeptidase B and dipeptidyl peptidase, 
necessary for Ang IV conversion, do not have exclusive miRNAs and thus may be subject to 
many regulatory effects.
A more in-depth examination of RAS-associated microRNAs, according to their functional 
impact in the RAS physiology is shown in Table 2. MiR-3163 targets the greatest number of 
RAS transcripts (N = 8) and may provide an over-arching level of regulation for the pathway 
Renin-Angiotensin System - Past, Present and Future178
as a whole, for example, in response to an external stimulus. miR-125-5p with five targets in 
common may function in a similar way, particularly since two of the targets are principal 
enzymes in RAS biochemistry. Yet, they make an ideal combination to block Ang II/AT1R and 
Ang IV/AT4R pathways and also shift the conversion of Ang I to Ang (1–7) via neprilysin and 
other peptidases to act on MasR.
In terms of RAS function, a group of microRNAs that can shift a predominant role of, for 
example, the Ang II/AT1R axis to opposing axes such as Ang(1–7)/MasR or Ang IV/AT4R 
could change cerebral blood flow, response to hypoxia and perhaps influence cognition and 
vice versa. Indeed, a panel of 17 miRNA families target aminopeptidase A and IRAP that 
could potentiate the formation of Ang IV (since aminopeptidase A converts Ang I and Ang II 
to Ang III, the Ang IV precursor for Ang IV). Thus, upregulation of those 17 miRNAs could 
modulate Ang III and IRAP to a greater extent than just one miRNA, such as miR-125. The 
net effect of reducing both ligand and receptor means that the function of the Ang IV/AT4R 
axis might be completely inhibited with likely deleterious effects on blood flow and cognitive 
performance. By contrast, downregulation of these miRNAs would increase the Ang IV/AT4R 
axis. The following section will discuss the effect of some specific miRNAs and their regula-
tory effects in RAS in the brain in health and in disease states.
RAS element Gene symbol Total miRNA families Unique miRNA families
Angiotensinogen AGT 85 11
Angiotensin 1 receptor 
(AT1R)
AGTR1 46 1
Angiotensin 2 receptor 
(AT2R)
AGTR2 78 5
Angiotensin 4 receptor 
(AT4R/IRAP)
LNPEP 252 28
Mas receptor MAS1 5 1
Angiotensin converting 
enzyme
ACE 59 4
Angiotensin converting 
enzyme 2
ACE2 54 4
Renin REN 21 2
Neprilysin MME 151 8
Aminopeptidase B RNPEP 29 0
Aminopeptidase N ANPEP 31 4
Aminopeptidase A ENPEP 158 13
Dipeptidyl peptidase DPP3 32 0
The total number of miRNAs represents miRNA families with binding sites at the 3′UTR region based on TargetScan 
[48]. Unique miRNAs are those considered solely with respect to other RAS elements.
Table 1. miRNA families targeting RAS elements.
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5. miRNAs and RAS: cerebrovascular regulation and cognitive function
5.1. MiR-1/206
The miR-1/206 family has been suggested to exclusively target AT1R in the RAS; however, 
it has an estimate of 790 other transcripts regulating other systems [48]. MiR-1 and miR-206 
are located in chromosomes 20 and 6, respectively and share homology in the seed region. 
RAS components microRNA families in common
ACE ACE2 ANPEP ENPEP 
LNPEP
1 miR-125-5p
ANPEP DPP3 ENPEP LNPEP 1 miR-670-3p
AGTR2 DPP3 LNPEP MME 1 miR-17-5p/20-5p/93-5p/106-5p/519-3p
ACE2 ENPEP LNPEP MME 3 miR-9-5p, miR-200-3p/429, miR-942-5p
AGTR2 LNPEP MAS1 1 miR-23-3p
ENPEP LNPEP MME 17 miR-26-5p, miR-30-5p, miR-132-3p/212-3p, miR-
194-5p, miR-204-5p/211-5p, miR-216-5p, miR-
376-3p, miR-376c-3p, miR-378-3p, miR-450b-5p, 
miR-518d-5p/519-5p, miR-522-3p, miR-580-3p, 
miR-653-5p, miR-1269, miR-3942-5p, miR-4766-3p
ACE2 ENPEP LNPEP 4 miR-374-5p/655-3p, miR-543, miR-4424, 
miR-1306-5p
ACE2 LNPEP MME 3 miR-374a-3p, miR-3194-3p, miR-5691
DPP3 LNPEP MME 5 miR-146-5p, miR-183-5p.1, miR-589-5p, miR-
876-5p, miR-2355-5p
ACE2 DPP3 LNPEP 1 miR-329-3p/362-3p
ACE2 ENPEP MME 1 miR-140-3p.1
ENPEP LNPEP 17 miR-9-3p, miR-19-3p, miR-29-3p, miR-34b-
5p/449c-5p, miR-105-5p, miR-122-5p, miR-144-3p, 
miR-320, miR-323-3p, miR-323b-3p, miR-382-3p, 
miR-494-3p, miR-514a-5p, miR-515-5p/519e-5p, 
miR-642a-5p, miR-3146, miR-5579-3p
DPP3 ENPEP 1 let-7-5p/98-5p
MAS1 1 miR-143-3p
ENPEP 13 miR-133, miR-142-3p.2, miR-219-5p, miR-371a-3p, 
miR-409-5p, miR-451, miR-496.1, miR-508-3p, 
miR-526b-5p, miR-877-5p, miR-1185-5p, miR-5094
ACE AGTR1 DPP3 1 miR-34-5p/449-5p
AGTR1 1 miR-1-3p/206
AGT AGTR1 AGTR2 DPP3  
ENPEP LNPEP MME RNPEP
1 miR-3163
From 164 combinations of overlapping targets and miRNAs in common, only 14 are included here, 12 which if increased 
would favour vasoconstriction and 2 would increase vasodilation. Others tend to influence multiple RAS pathways, an 
example, miR-3163, is given at the bottom of the table. miRNAs in bold are described further in the text.
Table 2. A summary of the subgroups of miRNAs according to their functional effect in the RAS.
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An evaluation of biochemical, cardiovascular and performance indexes of aerobic exercise 
 activity showed that some miRNAs were significantly increased. Specific correlations were 
found between miR-1, miR-133a and miR-206 and performance parameters, with miR-206 
having the strongest positive correlation [78]. MiR-1 was also found to be decreased 1.4-fold 
in post-mortem cardiac tissue from acute myocardial infarction patients [79]. In contrast, 
elevated plasma miR-1 levels were reported to predict heart failure after acute myocardial 
infarction although they returned to basal levels after medication [80].
In conditions of hypoxia such as infarcts, oxygen/glucose deprivation or with ischaemia/
reperfusion intervals, miR-1 is highly expressed [79, 80]. Under less stressful and non-life-
threatening situations, miR-206 is transcribed [78], both of them targeting AT1R to decrease 
Ang II-mediated vasoconstriction and in doing so increasing the supply of oxygen and glu-
cose to cells to prevent apoptosis.
MiR-1 overexpression inhibits contractility and proliferation of human vascular smooth mus-
cle cells (VSMCs) in vitro in a negative feedback loop [81, 82]. MiR-1 is downregulated in 
VSMCs from spontaneous hypertensive rats and its overexpression in vivo inhibits the pro-
liferation of VSMCs by targeting insulin-like growth factor 1 (IGF1) [83]. By contrast, miR-1 
upregulation enhances angiogenic differentiation of human cardiomyocyte progenitor cells 
[84]. The opposite effects of miRNA in different cell types may be explained by its cell-specific 
expression. Indeed, even if the miRNA is expressed under physiological conditions, varia-
tions to this will depend on local gene expression in a time- and cell type-dependent manner.
Evidence of peripheral and central roles for miRNAs was seen in a transgenic mouse model of 
cardiac-specific overexpression where miR-1 levels were increased not only in the heart but also 
in the hippocampus and peripheral blood. Furthermore, the mice showed cognitive impairment 
by downregulation of brain-derived neurotrophic factor (BDNF), a target of miR-1 [85], provid-
ing strong evidence for a role in endocrine signalling and association between vascular disorders 
and cognitive impairment. Nevertheless, it is unlikely that the response depends exclusively on 
miR-1 and it is not known as to whether the associations are primary or secondary in nature.
Collectively, miR-1 may serve to support protective mechanisms to adapt to adverse hypoxic 
insults and remodel the proteome as a result. Indeed, as mentioned above, remote ischaemic 
conditioning showed a high correlation between ischaemia/reperfusion intervals and the lev-
els of miR-1 in rats independent of BDNF mRNA and protein levels [69]. Hence, the miR-
1/206 family is likely important in cardioprotection, prevention of stroke and consequently 
cognitive impairment. Already it is used in screening for myocardial infarction, monitoring 
and response to therapy and also has a tentative therapeutic use for increasing vasodilation 
and angiogenesis [86, 87].
However, a solitary miRNA or miRNA-target interaction, such as between miR-1/206 and 
AT1R, is unlikely to be able to explain a complete physiological response. Inherent properties 
between miRNA transcription, interactions between their targets, the timing of their expres-
sion and subcellular localization provide a more likely explanation. A panel of dysregulated 
miRNAs is likely to cause an imbalance in targets, proteins and pathways involved. Such a 
characteristic combination of altered miRNAs may be useful as diagnostic tools. For example, 
a diagnosis of cholangiocarcinoma can now be made with 100% accuracy in the presence of a 
30-miRNA signature, three of them are useful for prognosis and monitoring and one of which 
has already entered a Phase I clinical trial as a potential treatment [88–91].
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5.2. MiR-143
The Mas receptor (MasR) has the lowest number of associated miRNAs, implying steady and 
tightly regulated homeostatic expression, although other post-transcriptional modifications 
are also likely to be involved in its regulation. In addition, miR-143 is exclusive to MasR in 
the RAS and interestingly, it has been found to be dysregulated in vascular disorders [92]. 
MiR-143 is enriched in cardiac stem cells before becoming localized to smooth muscle cells, 
including neural vascular smooth muscle cells (VSMC) in mice and its expression was found 
to be dependent on heartbeat rate in zebrafish [93, 94]. In human peripheral blood mono-
nuclear cells, miR-143 was upregulated in patients with essential hypertension and decreased 
in aortic aneurysms [95, 96]. Previous studies have focused on other targets of miR-143 in 
hypertension, yet the potential effect of miR-143 via the MasR remains elusive. Due to the 
small number of miRNAs attributed to the regulation of MasR, fluctuations in just one of 
them might have a significant effect on MasR protein levels.
5.3. MiR-132/212
Ang II regulated the miR-132/212 family in hypertensive rats and humans [97, 98] and this 
family has been attributed with both cardiovascular and brain-specific properties [99–103]. 
MiR-132/212 was initially thought to directly target AT1R with experimental studies dem-
onstrating a prevalent effect in the RAS, but new advances and criteria in miRNAs have 
shown that the effect was due to various downstream second messengers of AT1R activation. 
miRNA-132/212 has multiple targets including Ang II and endothelin-1 (ET-1) signalling [99]. 
Thus, miRNA-132/212 might be relevant in hypoxic conditions to control the vasoconstrictor 
effects of Ang II and ET-1. Indeed, transplantation of pericyte progenitor cells from human 
adult vena safena (Bristol pericytes) induced pro-angiogenic activity in endothelial cells, 
mediated by pericyte-produced miR-132 in response to hypoxia and taken up by endothelial 
cells passing through exosomes [104–106].
MiR-132 expression is also regulated by CREB [107, 108], enhances the frequency and ampli-
tude of excitatory potentials in neurons and increases dendritic length and arborization by 
targeting the brain-enriched GTPase-activating protein p250GAP [109, 110]. MiR-132 triggered 
marked increases in dendritic spine density, while either underexpression or overexpression of 
miR-132 caused cognitive impairment in supra-physiological conditions [100, 111]. Similarly, 
BDNF is regulated by CREB and a negative feedback interaction between the previously 
described miRNA-1/206 and miRNA-132/212 regulates BDNF expression in the brain [112]. 
Notably, miRNA-132/212 is also involved in the brain-immune axis and miR-132 mediates an 
anti-inflammatory effect by targeting acetylcholinesterase, thus increasing acetylcholine that 
reduces cytokine production [113, 114]. Furthermore, projections from basal forebrain neurons 
to cortical microvessels (nervi vasorum) and astrocytes containing primarily acetylcholine and 
nitric oxide synthase (NOS) have contributed to increased cerebral blood flow [77].
5.4. MiR-29
Another miRNA family dysregulated in cerebrovascular disorders and regulated by 
Ang II is miR-29 [74, 98]. The miR-29 family is linked to cardiac and vascular ageing and 
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 counteracts fibrosis by regulating extracellular matrix metallopeptidases [115]. Ang II 
increased miR-29b in cardiac fibroblasts with no effect in myocytes [116]. In the renal cortex 
of spontaneously hypertensive rats and in renal tubular epithelial cells, Ang II decreased 
the expression of miR-29b [117]. Notably, ET-1 decreased miR-29a expression in cardiac 
myocytes in vitro [118]. MiR-29b is increased in rat brain after focal ischaemia in vivo and 
in primary neurons exposed to oxygen/glucose deprivation in vitro [119]. Treatment of rats 
with peroxisome proliferator-activated receptor gamma (PPARγ) agonists protected against 
ischaemia-reperfusion injury by decreasing miR-29a and miR-29c levels; correspondingly, 
apoptosis was induced by overexpressing miR-29 [120]. However, mouse models of middle 
cerebral artery occlusion have inconsistently demonstrated increased and reduced miR-29 
levels [119, 121–123]. These conflicting findings have a number of possible explanations 
including animal age and species, as well as techniques and biosamples used, or other fac-
tors discussed below.
Despite the inconsistent evidence, a meta-analysis of microRNAs induced by aerobic exercise 
in humans evaluated left ventricle hypertrophy and proposed miR-29 family to be antihyper-
trophic and miR-34 family to be prohypertrophic [124]. MiR-34 was increased in patients with 
cardiovascular disorders in response to stress [125], which promotes apoptosis and cardiac 
autophagy [102]. By contrast, myocardial hypertrophy induced by Ang II/AT1R activation 
in rats is antagonized by miR-34 and its inhibition stimulated Ang II signalling via atrial 
natriuretic peptide [126]. AT1R activation increased intracellular calcium levels producing 
vasoconstriction in vascular smooth muscle cells. In addition, in endothelial cells, elevation 
of intracellular calcium levels contributes to the inhibition of nitric oxide production by atrial 
natriuretic peptide [127].
5.5. MiR-34
MiR-34 is involved in cardiac and endothelial senescence, characterized by decreased pro-
duction of the vasodilator nitric oxide by endothelial nitric oxide synthase, inflammation and 
resultant endothelial dysfunction [128]. MiR-34 promotes endothelial senescence by down-
regulating the histone deacetylase sirtuin-1 [129] and regulates cardiac contractile function 
during ageing and after acute myocardial infarction, as a result of inducing DNA damage 
and telomere attrition [130]. Transplantation of bone marrow-derived mononuclear cells from 
patients with cardiovascular disease induced cell death, while inhibition of the elevated levels 
of miR-34a ex vivo improved the functional benefit of transplanted bone marrow-derived 
mononuclear cells in mice after acute myocardial infarction in vivo [131]. Inhibition of miR-
34 also attenuated ischaemia-induced cardiac remodelling, atrial enlargement and improved 
systolic function [125, 132].
By contrast, miR-34 promoted differentiation of mouse embryonic neural stem cells to post-
mitotic neurons by targeting sirtuin-1 [133]. Along with miR-132/212, miR-34 was upregulated 
in human epilepsy screenings and pilocarpine-induced status epilepticus in rats [134–139], 
suggesting neuronal activity-based regulation. MiR-34 expression in the amygdala is also 
linked to repression of stress-induced anxiety [140], modulates ageing and neurodegenera-
tion in Drosophila [141] and is associated with cognitive impairment [142].
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The miRNA families described are functionally relevant in the development of cardiovascular 
and cerebrovascular disorders, some of which appear to link cerebral ischaemia, endothe-
lial dysfunction and cognitive impairment. Current therapy for cerebral ischaemia is limited 
to the use of recombinant tissue-plasminogen activator (tPA). Endogenous tPA is primarily 
expressed in endothelial cells and interactions between tPA and low-density lipoprotein recep-
tor-related protein (LRP) are important for the hippocampal activity-dependent strengthening 
of synapses known as long-term potentiation (LTP) [143]. AT1R activation causes increased 
expression of tPA inhibitor (tPA-I), which binds to LRP and blocks its interaction with other 
ligands, including apolipoprotein E and alpha 2-macroglobulin [144]. Furthermore, tPA-I lim-
its the maturation of proBDNF to BDNF and impedes protein synthesis-dependent late-phase 
LTP and hippocampal plasticity, mechanisms for learning and memory [145]. Chronic admin-
istration of tPA improved cognition in a APPswe/PS1 transgenic mice [146]. MiR-34 has two 
different binding sites at the 3′UTR of tPA-I, one of which has the highest probability of bind-
ing amongst the 108 miRNAs for this transcript. LRP1 is subject to regulation by 22 miRNAs, 
including miR-125 with one binding site and miR-212 with two binding sites [48].
There has been a recent consensus view on the roles of microRNAs, platelet and endothelial 
dysfunction in vascular disease and inflammation [147]. MiR-132/212 and miR-29 families 
target some proteins involved in endothelial dysfunction, such as the actin-related protein 2/3 
complex, platelet-derived growth factor and aquaporin 4 [48]; the latter two are particularly 
relevant in the maintenance of blood-brain barrier (BBB) integrity [148, 149]. Factors involved 
in BBB disruption include chronic hypertension, ischaemia, trauma, infections and inflam-
mation. Throughout the life course, these factors are likely to cause epigenetic modifications 
including miRNA fluctuations, leading to reduced protein translation and degradation of 
mRNA transcripts necessary for BBB integrity. BBB disruption is relevant in understanding 
the spectrum of clinical manifestations resulting from cerebrovascular disorders.
6. miRNAs challenges and considerations
More than 200 miRNAs have been found to be dysregulated in cerebrovascular disorders, 
with some inconsistency between studies [74–76, 150–152]. Inconsistencies likely relate partly 
to the size of the investigated cohorts, particularly since miRNAs may reflect the presence 
of comorbidities and hence statistical power and specificity would be lessened. Increasing 
the number of individuals and adding additional specificity (e.g. identifying disease-specific 
miRNAs as controls) might enable discrimination between the effects of dysregulated miR-
NAs. For instance, the ability to differentiate between changes in miRNAs associated with 
haemorrhagic and ischaemic cerebrovascular disorders and in the presence or absence of 
amyloid deposition or dementia, would be useful. Equally, changes in miRNA signatures 
could also explain pathophysiological processes in common, such as endothelial disruption 
and hypoxia due to hypoperfusion.
A second important factor in interpreting data across studies is that of methods used. miRNA 
detection with high sensitivity and specificity is demanding. The target sequence is present in 
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the primary transcript, the precursor and the mature miRNA; some miRNAs within the same 
family differ by just a single nucleotide [153, 154]. Profiling can be achieved via three major 
methods: amplification using quantitative real-time polymerase chain reaction (qRT-PCR), 
hybridization based on microarrays and sequencing by next-generation sequencing (NGS) 
technologies [153, 155]. Due to the small size of miRNAs, guanidine-cytosine (GC) content 
and similar target sequence, hybridization-based methods lack specificity. NGS technologies 
have provided a considerable aid to advance the field of miRNA, elucidating new miRNAs 
and applying new criteria for the RNA sequences to be recognized as miRNAs. Studies eval-
uating sensitivity, specificity, quantification accuracy and reproducibility of different assays 
have shown that miRNA levels were dependent on the nature of the technique and also with 
differences between commercial kits [154, 156, 157]. Despite the advantages of NGS, a valida-
tion method is highly recommended for those dysregulated miRNAs in large-scale screenings. 
Although there is no specific consensus paper, qRT-PCR has been widely cited as the gold stan-
dard in miRNA research, providing specificity between isomiRs and using stem-loop primers 
for discrimination from primary miRNAs, pre-miRNAs and degraded mRNA [153, 158].
Another factor is the handling and sample source of miRNAs that are cell type specific and 
thus, the proportion of different cells contained in a sample can vary. In addition, blood con-
tains high levels of RNase activity; while miRNAs are protected from RNase under normal 
conditions, their extraction causes immediate degradation if extracted and spiked back to 
plasma [153]. Other pre-analytic variables might also affect its profiling, such as centrifuga-
tion [159]. Collection and handling procedures are relevant to reliably detect dysregulated 
miRNAs. Exosomal RNA is protected by RNase A treatment and exosomes provide a consis-
tent source of miRNA for disease biomarker detection [160]. Sources like formalin-fixed tissue 
have been found to be highly reliable [79, 153].
In studies of disease, the pathological stage of the disease, post-mortem status and the ago-
nal state prior to death should also be considered as miRNAs measured could represent 
causal and/or responsive mechanisms. Thus, there is a need to discriminate between miR-
NAs produced under normal conditions in different cell types for effective comparisons with 
those regulated by an environmental insult (e.g. hypoxia), those regulated by the activation 
of a receptor (e.g. AT1R) or by a common downstream regulator (e.g. CREB). Indeed, dur-
ing the natural history of a disease, microRNAs will likely fluctuate and their final signa-
ture might represent a retrospective picture of various protective mechanisms and aberrant 
dysregulations.
Finally, the effects of miRNAs on their targets should be viewed in the context of a whole 
functional analysis [161]. For instance, renin-sensitive microRNAs correlate with atheroscle-
rosis plaque progression [162]. It is conceivable that only a specific combination of microR-
NAs produces a relevant physiological response. Several outcomes in miRNA research 
appear to be the result of well-defined miRNA-target-related effects. Nevertheless, the impact 
of a single miRNA via a specific target is related to the total number of different transcripts it 
targets and also by the number of other miRNAs that share the same target. It is reasonable to 
attribute a functional characteristic to a miRNA, based on the experimental outcome, such as 
in  luciferase assays. However, luciferase assays are not able to differentiate between canonical 
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and non-canonical binding sites, neither if the effects are a result of direct miRNA binding to 
the transcript or by modifying transcription factors.
Furthermore, the experimental outcome will depend on the mRNAs expressed in that cell 
at that time. For instance, 213 miRNAs can bind at the 3′UTR of the anti-apoptotic protein 
BCL-2, whereby one could assume that those 213 miRNAs are pro-apoptotic by downregu-
lating BCL-2. However, one of those 213 miRNAs alone could have several hundred tar-
gets, some of which promote apoptosis and others favouring survival. Thus, examination 
of the complete array of targets is needed to provide a functional analysis including an 
assessment of overlapping targets between miRNAs [161, 163]. Another consideration is 
the probability rate by which a miRNA binds to the 3′ UTR. Agarwal et al. developed a 
score based on 14 features (total context score) to allow determination of the probability of 
miRNA binding and categorization of miRNAs into percentiles based on the total context 
score [48]. Finally, it is prudent to consider the number of copies of a miRNA expressed. 
Some miRNAs, such as miR-124 and miR-128, are highly expressed up to 30,000–50,000 
copies per neuron, while others can be as low as 1–2 copies per neuron [29]. Therefore, the 
biological impact of miRNAs relies on the combinatorial signature, the number of miRNA 
copies expressed, their affinity for different transcripts and the existing mRNA environment 
accessible for remodelling.
7. Conclusions
In summary, miRNAs are essential for cell fate and differentiation and their effects depend 
on the mRNA environment expressed, which can be transient over time and subject to dys-
regulation that may lead to disease. As a highly dynamic and interactive process, epigenetics 
and particularly miRNAs play a significant role in cognition [164, 165]. Drosha and Dicer 
are expressed throughout the brain with a higher expression in the hippocampus and den-
tate gyrus [166]. Functional analysis through bioinformatics and the use of next-generation 
sequencing could reveal a miRNA signature that helps to explain the effects on pathways 
and the fluctuations seen over the development of a specific disease. This could allow iden-
tification of a small group of miRNAs that are determinant in the clinical manifestation and 
therefore potential targets for diagnosis and therapeutic intervention. These would have a 
great advantage as therapies due to their small size and lipidic transport across the BBB, 
direct intracellular interaction with the transcriptome and may be able to facilitate regenera-
tion while obviating the consequence of a degenerative microenvironment.
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